Consequentially, one recruiting trial for subtype-specific PI3K inhibition in acute leukemia interrogates the efficacy of the PI3Kα inhibitor BYL719 in combination with MEK162 (clinicaltrials.gov, ID#NCT01449058). The gene discussed is PIK3CA; the disease is acute leukemia.